Stockwinners Market Radar for November 15, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST Universe Pharmaceuticals Inc trading halted, news pending

19:50 EST Bluejay Diagnostics Inc trading halted, news pending

18:18 EST Procaps Group receives Nasdaq listing determination, will request hearing - Procaps Group that, on November 13, the company received formal notice from the Listing Qualifications Department of The Nasdaq Stock Market that, based upon the company's failure to timely file the Form 20-F for the fiscal year ended December 31, 2023 with the U.S. SEC, the company no longer satisfied Nasdaq Listing Rule 5250(c)(1) and its securities are therefore subject to suspension and delisting unless the company timely requests a hearing before and a further stay of any suspension action at least pending the ultimate conclusion of the hearings process from the Nasdaq Hearings Panel. The company plans to timely request a hearing before the Panel as well as a further stay. The Panel will review the request of an extended stay and notify the Company of its determination as soon as practicable, but in any event no later than 15 calendar days following the deadline to request the hearing. Nasdaq notified the company that hearings are typically scheduled to occur approximately 30-45 days after the date of the hearing request. Until the Panel makes a determination regarding the stay request, the company's securities will continue to trade on Nasdaq. The company continues to work diligently to complete the previously disclosed independent investigation and to file the Form 20-F with the SEC as soon as practicable.

17:56 EST Grindr CFO Mehta-Krantz sells 60,776 common shares - In a regulatory filing, Grindr CFO Vandana Mehta-Krantz disclosed the sale of 60,776 common shares of the company on November 13 at a price of $14.29 per share.

17:31 EST Syndax confirms FDA approval of Revuforj for acute leukemia - Syndax Pharmaceuticals announced that the U.S. FDA has approved Revuforj as the first and only menin inhibitor for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application received approval through the FDA's Real Time Oncology Review program.

17:09 EST MSG Entertainment CFO Michael Grau to leave company effective November 20 - On November 13, Madison Square Garden Entertainment and Michael Grau, the company's Executive Vice President and CFO, agreed that he will be leaving the company, and effective November 20, will cease to be CFO. His separation is not the result of any disagreement with the company's independent auditors or any member of management on any matter of accounting principles or practices, financial statement disclosure or internal controls. Lee Weinberg will serve as the company's Interim CFO effective November 20. Weinberg has served as Senior Vice President, Business & Financial Operations of the company since the company's spin-off from Sphere Entertainment Co. in April 2023.

16:32 EST LuxUrban Hotels announces 1-for-70 reverse stock split - LuxUrban Hotels announced that it will effectuate a one-for-seventy reverse stock split of its common stock. This reverse stock split was approved by stockholders at the special meeting held on November 12, and will be effective at the opening of trading on November 20. The reverse stock split is part of LuxUrban Hotels' strategy to strengthen its position within the Nasdaq Capital Markets, improve the stock's trading profile, and position the company for future growth and expansion opportunities. Following the reverse split, the number of shares of common stock issued and outstanding will be reduced from approximately 151.85M to approximately 2.17M shares. In addition, stockholders approved a proposal to waive the 19.99% share limitation under Nasdaq Rule 5635(d), allowing the company to issue additional shares of common stock upon the conversion of certain convertible promissory notes and the exercise of outstanding warrants. This approval enables LuxUrban to maintain its compliance with Nasdaq listing standards while maximizing the flexibility of its financing arrangements. The trading symbol for LuxUrban's common stock on the Nasdaq Capital Market will remain "LUXH." Stockholders who would own a fraction of a share as a result of the reverse stock split will instead receive cash in lieu of a fractional share.

16:17 EST CRH acquires Dutra Materials, terms not disclosed - CRH announced the acquisition of Dutra Materials in San Rafael, California. This acquisition expands CRH's Americas Materials Solutions business and enhances its ability to provide integrated solutions to customers in northern California. Dutra Materials complements CRH's Americas Materials Solutions business in the Western U.S., bringing additional strategic aggregate reserves and asphalt production capabilities to service the northern California construction market. "We are delighted to welcome Dutra Materials into the CRH family. Following our entry into the state of California earlier this year via the acquisitions of BoDean Company and Northgate Ready Mix, we are excited to expand our presence in California and further enhance our ability to provide integrated solutions to customers in this attractive market," said Scott Parson, President, Americas Materials Solutions, CRH.

16:12 EST Gladstone Commercial COO Terry Lee Brubaker to retire - Gladstone Commercial Corporation announced that Terry Lee Brubaker will be retiring as Chief Operating Officer of the Company effective December 2, 2024. Mr. Brubaker is also retiring as director and executive officer of Gladstone Management Corporation, the Company's investment adviser, and as a member of the board of managers and an executive officer of Gladstone Administration, LLC, the Company's administrator, also effective December 2, 2024. Following Mr. Brubaker's departure, Michael LiCalsi, the Company's General Counsel and Secretary, who also serves as Gladstone Administration's President, General Counsel and Secretary, will assume certain additional operational responsibilities while Gladstone Management will conduct a national search for a Chief Investment Officer to fill Mr. Brubaker's investment committee responsibilities. Chairman and Chief Executive Officer, David Gladstone, stated, "Terry has been an integral part of the Gladstone family since inception. His tenure at Gladstone has been marked by remarkable growth and steadfast dedication. Terry's commitment to our funds and our shareholders will be missed."

16:11 EST Gladstone Investment COO Terry Lee Brubaker to retire - Gladstone Investment Corporation announced that Terry Lee Brubaker will be retiring as Chief Operating Officer of the Company effective December 2, 2024. Brubaker is also retiring as director and executive officer of Gladstone Management Corporation, the Company's investment adviser, and as a member of the board of managers and an executive officer of Gladstone Administration, LLC, the Company's administrator, also effective December 2, 2024. Following Brubaker's departure, Michael LiCalsi, the Company's General Counsel and Secretary, who also serves as Gladstone Administration's President, General Counsel and Secretary, will assume certain additional operational responsibilities while Gladstone Management will conduct a national search for a Chief Investment Officer to fill Mr. Brubaker's investment committee responsibilities. Chairman and Chief Executive Officer, David Gladstone, stated, "Terry has been an integral part of the Gladstone family since inception. His tenure at Gladstone has been marked by remarkable growth and steadfast dedication. Terry's commitment to our funds and our shareholders will be missed."

16:07 EST Federal Realty COO Jeffrey Berkes to leave company effective December 31 - Federal Realty Investment Trust announced that Jeffrey Berkes, the company's President and COO, will be leaving the company effective December 31. The position of COO will not be backfilled.

16:05 EST Perception Capital Corp IV trading halted, news pending

16:00 EST Armlogi Holding Corp trading resumes

15:01 EST FS Bancorp authorizes additional repurchase of up to $5M in shares - FS Bancorp, the holding company for 1st Security Bank of Washington, announced that the company has completed the $5.0M repurchase program announced on July 11, 2024. The company also announced that its board of directors has authorized an additional repurchase of up to $5.0M in shares of the company's outstanding shares of common stock in the open market, in privately negotiated transactions or shares withheld upon the exercise of equity awards from time to time over a 12-month period until October 31, 2025, at such prices as may be determined by the company's management. The repurchase program will commence no sooner than the third trading day after the public announcement of this repurchase program, the company stated.

13:38 EST Marshall & Ilsley Corporation trading resumes

13:08 EST NYSERDA issues RFI to gauge market interest in nuclear energy development - The New York State Energy Research and Development Authority announced the issuance of a Request for Information to gauge market interest in activities to develop advanced nuclear energy technologies in New York State. Through this RFI, NYSERDA seeks to identify entities that are currently pursuing or interested in a potential role in advanced nuclear energy development. Responses will help inform next steps following the Future Energy Economy Summit held in September at Governor Kathy Hochul's direction. Entities encouraged to respond include: stakeholders who may be considering advanced nuclear solutions, such as users of large electric loads, industrial heat, and hydrogen - both those already active in New York and those considering establishing operations in New York; supply chain companies that could provide critical components for development of advanced nuclear energy projects in New York; potential host communities for nuclear reactors or supply chain projects; workforce development and training entities; nuclear generation project developers; financing/funding entities; and research and development entities including laboratories, universities and private entities. Responses are preferred by December 16, 2024, to inform future engagement opportunities and planning. Publicly-traded companies in the space include Nano Nuclear Energy (NNE), Nuscale Power (SMR), and Oklo (OKLO). Reference Link

13:02 EST Compass Minerals up 22% after Reuters reports on go-private talks

12:23 EST GE Aero, NASA partnering on flight tests to accelerate contrails understanding - GE Aerospace and NASA are partnering on a series of flight tests to help further the aviation industry's understanding of contrails, using new test methods and technologies. "GE Aerospace is proud to once again team up with NASA to be at the forefront of innovation for the future of more sustainable flight," said Arjan Hegeman, general manager of future of flight technology for GE Aerospace. "Understanding how contrails act in-flight with the latest detection technology is how we move innovation forward. These tests will provide critical insight to advance next generation aircraft engine technologies for a step change in efficiency and emissions."

12:00 EST Daily S&P Biotech Bear 3x Shares rises 13.1% - Daily S&P Biotech Bear 3x Shares is up 13.1%, or 80c to $6.90.

12:00 EST Bloom Energy rises 46.8% - Bloom Energy is up 46.8%, or $6.22 to $19.50.

12:00 EST Phreesia falls -17.3% - Phreesia is down -17.3%, or -$3.62 to $17.38.

11:42 EST Meta says Views to become primary metric on Facebook - Meta Platforms' Facebook said Thursday that creators will now have a single distribution metric for all content types that's calculated the same way across Facebook and Instagram. The new metric - called Views - tells you the number of times a reel or video was played or the number of times photo or text posts were on screen, and aligns with Instagram's recently updated metrics. Views streamlines the various unique content distribution metrics into one, helping you understand how well your content is resonating regardless of format or Meta platform, the company said. Views also capture when people look at your content multiple times, telling you more about how interesting or entertaining it is. "On reels and videos, Plays will now be called Views," the company said. "How Views are calculated will not change, so you should not see any meaningful changes to this metric other than the new name. As part of this update, we're removing the separate replays metric. For Stories, photo or text posts, Views will replace Impressions. For these non-video formats, Views are calculated as the number of times they appear on a person's screen, including repeat views. So for example, a person viewing a photo three separate times in the same day would count as three Views for that photo instead of one Impression. This means you may notice your Views are higher than your previous impression counts. In addition to the new Views metric, we're updating our video metrics. Minutes Viewed and Average Minutes Viewed will replace Watch Time and Average Watch Time. Watch Time is the total amount of time the reel or video was played, including any time spent replaying the reel or video. It captures how long people watch down to the second, whereas Minutes Viewed rounded to the closest minute. Other metrics like Reach, 3-second views, 1-minute views, Reactions, Comments and Shares will remain unchanged. You can expect to see all these changes within Insights in Meta Business Suite and Professional Dashboard over the next few weeks. Views will be additionally available across all ads measurement surfaces for all ad formats." Reference Link

11:36 EST Soros boosts stake in AstraZeneca, exits Apple position - George Soros' Soros Fund Management disclosed in an SEC filing its holdings as of September 30, 2024. Soros' new buys during the third quarter included, by size of position, Global Payments (GPN), Salesforce (CRM), and Synchrony Financial (SYF). Soros exited a number of positions during the quarter, including Apple (AAPL), Agilent Technologies (A), Biomarin Pharmaceuticals (BMRN), PG&E (PCG), and TSMC (TSM). Soros increased its stake in a number of holdings, including AstraZeneca (AZN), AerCap (AER), Alibaba (BABA), GFL Environmental (GFL), and JD.com (JD) . Soros reduced its stake in a number of holdings, including by size of previous position, Liberty Broadband (LBRDK), Alphabet (GOOGL), Axonics (AXNX), and EchoStar (SATS).

11:13 EST Barinthus announces results from ongoing Phase 2b HBV003 trial - Barinthus Biotherapeutics announced "the most significant data so far" from the ongoing Phase 2b HBV003 clinical trial. The data will be presented by Dr. Chun-Jen Liu as an oral presentation on November 18, at 17:30 PT at the American Association for the Study of Liver Diseases, or AASLD, Liver Meeting 2024. The HBV003 study is fully recruited with a total of 121 participants, including 69 participants who had entered the trial with HBsAg levels below 200 IU/mL. The study is evaluating different dosing regimens of VTP-300 in combination with low-dose nivolumab, an anti-PD-1 monoclonal antibody. The new data showed that as of data cut off, eight participants were reported with complete HBsAg loss and two participants met the criteria for functional cure. Uniquely, two of the eight participants with HBsAg loss, became positive for anti-hepatitis B antibodies that they did not have before, including one of those who met functional cure criteria. The data from this ongoing study indicate that stronger responses may happen in participants treated with the combination of VTP-300 and a low dose of the anti-PD1 antibody nivolumab. "These Phase 2 data are incredibly encouraging and highlight the ability of VTP-300 to stimulate the immune response and induce sustained reductions in HBsAg to the point of meeting functional cure criteria," said Dr. Nadege Pelletier, Chief Scientific Officer of Barinthus Bio. "Moreover, the finding that one of the participants meeting functional cure criteria had antibodies against hepatitis B is promising as HBsAb positivity is associated with long-term control of the infection by the immune system."

11:11 EST Arbutus Biopharma announces new data from IM-PROVE I Phase 2a trial - Arbutus Biopharma announced new data from its IM-PROVE I Phase 2a clinical trial showing that six doses of imdusiran, the company's RNAi therapeutic candidate, and 24 weeks of pegylated interferon alfa-2a, or IFN, a standard-of-care immunomodulator, added to ongoing nucleos(t)ide analogue therapy, led to a functional cure rate of 50%, or 3 of 6, in HBeAg-negative patients with baseline HBsAg levels less than 1000 IU/mL, and an overall functional cure rate of 25%. Patients with HBsAg levels less than 1000 IU/mL represent a significant portion of the cHBV population. These data will be presented as a late-breaker poster presentation on November 18, 2024 at The American Association for the Study of Liver Diseases, or AASLD. "We are extremely excited to have functionally cured these patients with the imdusiran and interferon treatment regimen. There is a significant need for a functional cure for the more than 250 million patients chronically infected with HBV worldwide," commented Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma. "Excess production of surface antigen is believed to contribute to host immune exhaustion, resulting in inadequate immune response and failure to suppress the virus. These data support our belief that lowering surface antigen with imdusiran and incorporating an immunomodulator in the treatment regimen provides a functional cure in some patients with cHBV. We thank all the patients and investigators who participated in this clinical trial."

11:07 EST Akero to showcase new analyses of Phase 2b HARMONY study at AASLD - Akero Therapeutics announced results of analyses supporting the clinical activity of efruxifermin in metabolic dysfunction-associated steatohepatitis in one oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases The Liver Meeting, held November 15-19, 2024, in San Diego. "The data to be presented at The Liver Meeting show that 96 weeks of treatment with EFX has the potential to drive substantial reversal of disease in patients living with pre-cirrhotic MASH," said Kitty Yale, chief development officer of Akero. "We are encouraged by consistent improvements observed across a number of clinically established markers of liver health and the corroboration of conventional histopathology assessments with Artificial Intelligence (AI)-based digital pathology. We believe these new analyses provide further evidence for the potential of EFX to be a differentiated therapy for MASH." One poster presents an orthogonal analysis of baseline, week 24, and week 96 liver biopsies from HARMONY by HistoIndex. This analysis corroborates the pattern of anti-fibrotic effects observed with conventional pathology after treatment with EFX for 24 or 96 weeks. Specifically, a quantitative analysis by qFibrosis across different zones of the liver revealed EFX-associated reductions in fibrosis primarily in the perisinusoidal and periportal zones that were sustained or expanded from weeks 24 through 96 for participants, regardless of baseline fibrosis stage. The second poster presentation shows that 30% of participants receiving EFX 50mg for 96 weeks had almost complete reversal of MASH-related disease, as indicated by reversal of fibrosis to Fless than or equal to1, resolution of MASH, and normalization of liver fat content to less than or equal to5%, compared to 0% of participants on placebo. In addition, 100% of participants who received EFX 50mg for 96 weeks were categorized as "low risk of progressive MASH" by FibroScan-AST score. In contrast, 48% of participants receiving placebo remained at high or indeterminate risk of progressive MASH. Based on the same analyses, the extent of reversal of disease relative to placebo was smaller for participants receiving EFX 28mg than 50mg. "We believe that, taken together, the suite of presentations provides evidence supporting the consistent anti-fibrotic effects of EFX observed to date in the HARMONY trial as well as the the clinical activity and generally favorable safety profile of EFX in patients with precirrhotic MASH (F2-F3). The ongoing Phase 3 SYNCHRONY program is designed to confirm a favorable benefit-risk profile and support marketing applications for EFX for the treatment of MASH," said Yale.

11:06 EST Gilead announces data from interim analysis of Phase 3 ASSURE study - Gilead Sciences announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81%, or 30 out of 37, of participants with primary biliary cholangitis, or PBC, treated with Livdelzi achieved a composite biochemical response, demonstrating significant improvements in a key measures of PBC progression. Additionally, 41%, or 15 out of 37, of participants achieved normalization of alkaline phosphatase, or ALP, levels, a critical biomarker of liver function. These findings were unveiled as a late-breaker presentation at The Liver Meeting 2024 hosted by the American Association for the Study of Liver Diseases, or AASLD. "Gilead has a legacy of bringing groundbreaking treatments to people in need and Livdelzi is the first and only treatment to demonstrate statistically significant and durable improvements in both pruritus and markers of cholestasis related to the risk of disease progression," said Timothy Watkins, MD, MSc, Vice President, Clinical Development, Inflammation Therapeutics, Gilead Sciences. "With Livdelzi, we've introduced an effective and well tolerated option for people living with PBC, offering an important novel treatment option. We remain committed to advancing innovative therapies that provide real hope and improved outcomes for people facing this challenging liver disease."

11:02 EST Vir Biotechnology reports 'positive' end-of-treatment data from MARCH study - Vir Biotechnology announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa, in participants with chronic hepatitis B. The study demonstrated "promising" rates of hepatitis B surface antigen loss, or seroclearance, in participants with low baseline HBsAg in both combination regimens, the company said. The efficacy and safety profile support continued development to evaluate the potential to achieve a functional cure. Detailed data will be presented in a late-breaking oral presentation at the American Association for the Study of Liver Diseases, or AASLD, The Liver Meeting, on November 18 at 5:00 p.m. PT. Vir Biotechnology will host an investor conference call on November 19, at 8.15 a.m. ET, the company noted. "At Vir Biotechnology our ambition is to develop a functional cure for chronic hepatitis B following a finite treatment regimen. The MARCH data suggests that tobevibart and elebsiran can clear HBsAg and re-ignite the immune system, producing antibodies to potentially keep the virus under control," said Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, Vir Biotechnology. "We are encouraged by these results and eagerly anticipate the functional cure data in 2025, as it will be decisive for the next steps of clinical development."

10:43 EST Lone Pine takes new positions in Salesforce and Starbucks, exits Mastercard - Stephen Mandel's Lone Pine Capital disclosed las night in an SEC filing its holdings as of September 30, 2024. The fund's new buys during the third quarter included, by size of position, Salesforce (CRM), Lennar (LEN), Starbucks (SBUX), Workday (WDAY), and Talen Energy (TLN). Lone Pine exited four positions during the quarter, including by size of previous position, Mastercard (MA), Bath & Body Works (BBWI), McKesson (MCK), and AvidXchange (AVDX). The fund increased its stake in many holdings, including by size of previous position Meta Platforms (META), Constellation Energy (CEG), Amazon (AMZN), Ares Management (ARES), and LPL Financial (LPLA). Lone Pine reduced its stake in multiple holdings, including by size of previous position, TSMC (TSM), Microsoft (MSFT), AppLovin (APP), ASML (ASML), and Philip Morris (PM). The fund's top holdings as of September 30, in order of size, were Meta Platforms, Amazon, Vistra (VST), TSMC, and Microsoft.

10:04 EST GM's Cruise to pay $500,000 fine to DOJ, admits submitting false records - GM's Cruise LLC, an autonomous vehicle company based in San Francisco, has agreed to resolve a criminal charge in federal court for providing a false record to National Highway Traffic Safety Administration with the intent to impede, obstruct, or influence the investigation of a crash involving one of Cruise's autonomous vehicles. A criminal information charges Cruise with the offense, which Cruise has agreed to resolve through a deferred prosecution agreement and payment of a $500,000 criminal fine. "Federal laws and regulations are in place to protect public safety on our roads. Companies with self-driving cars that seek to share our roads and crosswalks must be fully truthful in their reports to their regulators," said Martha Boersch, Chief of the Office of the U.S. Attorney's Criminal Division. The criminal information alleges that Cruise falsified records in a federal investigation under the jurisdiction of NHTSA within the U.S. Department of Transportation. The criminal investigation and prosecution against Cruise is being resolved with a deferred prosecution agreement in which Cruise admits and accepts responsibility for the charge in the information. Under the deferred prosecution agreement, Cruise is required to pay a $500,000 criminal fine, cooperate with government investigations, implement a Safety Compliance Program, and provide annual reports to the United States Attorney's Office on implementation and remediation. If Cruise fails to completely perform or fulfill its obligations under the agreement during the agreement's three-year term, the U.S. Attorney's Office can proceed with prosecution of the charged offense. Reference Link

10:00 EST Phreesia falls -10.9% - Phreesia is down -10.9%, or -$2.29 to $18.71.

10:00 EST Daily S&P Biotech Bear 3x Shares rises 8.9% - Daily S&P Biotech Bear 3x Shares is up 8.9%, or 54c to $6.64.

10:00 EST Bloom Energy rises 35.7% - Bloom Energy is up 35.7%, or $4.74 to $18.02.

09:48 EST Despegar.com rises 12.0% - Despegar.com is up 12.0%, or $1.78 to $16.64.

09:47 EST Spectrum Brands falls -6.6% - Spectrum Brands is down -6.6%, or -$6.24 to $87.62.

09:47 EST Oklo falls -15.7% - Oklo is down -15.7%, or -$3.75 to $20.13.

09:33 EST First National Corp. raises quarterly cash dividend 3% to 15.5c per share - The Board of Directors of First National Corporation declared a quarterly cash dividend of 15.5c per share on November 13, 2024, a 3% increase compared to the quarterly dividend paid on September 13, 2024. This is the tenth consecutive year the Company has increased its dividend to shareholders. The dividend is payable on December 13, 2024, to shareholders of record as of November 29, 2024.

09:32 EST TAT Technologies trading halted, volatility trading pause

09:27 EST Organogenesis 'commends' final local coverage determinations - Organogenesis commends the decision by the U.S. Centers for Medicare & Medicaid Services on local coverage determination based on peer-reviewed and evidence-based data of clinical efficacy. The LCD covers skin substitute grafts/cellular and tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the Medicare population and is now set to become effective on February 12, 2025. Organogenesis offers 4 products for DFUs, including NuShield, and 2 for VLUs.

09:22 EST KKR receives support from Fuji Soft for second tender offer - KKR announced that in connection with its two-stage tender offer scheme for the common shares and share options of Fuji Soft through FK Co., the offeror, an entity owned by investment funds managed by KKR, will conduct the second tender offer at a price of 9,451 yen per common share. KKR expects to commence the second tender offer as soon as the middle of next week. The board of directors of Fuji Soft resolved to support the second tender offer and to recommend that shareholders and share option holders of the company tender their shares and share options into it. The board also resolved to oppose the proposal by Bain Capital. Both resolutions were unanimous. The second tender offer follows the completion of the first tender offer, through which KKR acquired 21,413,302 common shares and share options totaling 718,600 common shares on an as-converted basis to become Fuji Soft's largest shareholder. The first tender offer received significant support from advisors, directors and officers of Fuji Soft, who tendered 90% of their share options. The offeror raised the tender offer price per common share to 9,451 yen with the aim of accelerating the privatization process as Fuji Soft's shares have stayed above the price of the first tender offer. The price of 9,451 yen per share represents a premium of 125.8% over the simple average closing price of Fuji Soft's stock for the 12 months prior to October 2, 2023. All shareholders and share option holders who tendered into the first tender offer will be made whole if the second tender offer succeeds and KKR achieves a 53.22% stake across both tender offers.

09:19 EST Via Renewables announces commencement of tender offer - Via Renewables is commencing a tender offer to purchase up to 800,000 shares of its 8.75% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, par value $0.01 per share, at a purchase price of $22.50 per share, in cash, less applicable withholding taxes and without interest. The number of shares proposed to be purchased in the tender offer represents approximately 22.4% of the Company's currently outstanding Series A Preferred Stock. Pursuant to the tender offer, holders of the Company's Series A Preferred Stock may tender all or a portion of their shares. Holders will receive the purchase price in cash, subject to applicable withholding and without interest, subject to the conditions of the tender offer, including the provision relating to proration in the event that the number of shares properly tendered and not properly withdrawn exceeds 800,000. The proration of Series A Preferred Stock tendered in the tender offer is described in the Offer to Purchase and in the Letter of Transmittal relating to the tender offer that will be distributed to holders of Series A Preferred Stock and filed with the U.S. Securities and Exchange Commission. The tender offer is not conditioned upon receipt of any financing or on any minimum number of shares being tendered; however, the tender offer is subject to a number of other terms and conditions specified in the Offer to Purchase. The tender offer and withdrawal rights will expire at 5:00 p.m., New York City time, on Tuesday, December 17, 2024, unless extended or terminated.

09:17 EST PHI Group engages Ecome International for geomagnetic energy solutions - PHI Group announced that Philux Global Energy and Ecome International have signed a Memorandum of Understanding to grant EIC a non-exclusive right to sell and distribute geomagnetic energy products manufactured, produced, or sold by Philux Global Energy in the Kingdom of Thailand. Initially EIC will primarily focus on providing Philux Global Energy's geomagnetic energy products to Thai industrial zones. PGE's core technologies will include Schumann magnetic resonance, utilizing energy from lightning in the ionosphere, storage in the natural atmosphere as Energy Storage Systems, acceleration of Muon particles in the module, taking advantage of wave nodes and wave troughs in the process of transmitting energy in the form of multi-frequency impulses. The distinctive advantages of this "Multi-Impulse Energy System" include: not depending on weather conditions, does not require much land and/or water surface, no need for large space, easy to transport, electromagnetic compatibility with living organisms and humans, no harm effects to the health of humans, livestock, pets, or vegetation, no waste or greenhouse gas emissions, no heat generation, no noise generation, easy know-how protection with quantum encryptions, easy to set up virtual power plants by using proprietary modules to coordinate output synchronously, easy to establish wireless power transmission systems with huge capacity without heat loss at close range, suitable setup for two-way recharging for electric cars. Philux Global Energy plans to provide these "pure energy" solutions to support the energy transition in sectors ranging from electric vehicles to aerospace, aiming to cut dependency on traditional fuel sources while contributing to climate action goals. Our approach leverages proprietary technology to provide scalable energy options that remain unaffected by weather and environmental limitations, promising a low-impact energy source suitable for various industrial needs.

09:11 EST Mullen Automotive's Bollinger partners with NAFG - Mullen Automotive announces it has partnered with National Auto Fleet Group, NAFG, to sell its all-electric, Class 4 Bollinger B4 commercial trucks to government agencies through NAFG's Sourcewell-awarded contract. "Bollinger Motors is excited to work with National Auto Fleet Group to bring the Bollinger B4 to one of our most important customer groups, government entities at all levels," said Jim Connelly, chief revenue officer of Bollinger Motors. "Government agencies and municipalities are often early adopters for electrification and electric vehicle fleets. We look forward to partnering with NAFG, and their history of bringing innovative products and solutions to this important segment."

09:10 EST Fortinet expands global presence with new company-owned hub in Atlanta, GA - Fortinet announced the opening of a new building in Atlanta, Georgia, GA. As the newest Fortinet-owned facility to open this year, the company remains deeply committed to its global expansion strategy, aiming to drive innovation and strengthen collaboration for Fortinet's customers, partners, employees, and other key stakeholders around the world. John Whittle, Chief Operating Officer at Fortinet: "With our new space in Atlanta set to become one of our global Innovation Hubs, we'll be able to better serve our growing customer base in this region as we build on the partnerships created across industries in Georgia over the past 24 years. Through our global Innovation Hubs, Fortinet is committed to enhancing our infrastructure and innovation to continue to deliver unmatched experiences and solutions to customers worldwide. We're excited to be part of this vibrant community, helping to contribute to Atlanta's position as a hub for business and technology."

09:07 EST Landstar System appoints Joe Beacom as president, Landstar System Holdings - Landstar System announced two changes to its executive leadership team, effective December 1, 2024: Joe Beacom has been named President of Company subsidiary, Landstar System Holdings, Inc., and each of its agent-based transportation services companies. Matt Miller has been named Vice President and Chief Safety and Operations Officer of the Company, succeeding Mr. Beacom in that role. With his promotion to the Company's executive leadership team, Mr. Miller will have enterprise responsibility for all operational matters relating to Landstar's capacity network of truck owner-operators and third-party truck brokerage carriers. Mr. Miller's expanded role continues to include responsibility for safety, compliance, trailer maintenance and utilization and operations solutions at Landstar. During his 15-year career at the Company, Mr. Miller has held positions of increasing responsibility in safety, operations, finance and risk management.

09:04 EST Allegiant Travel reports preliminary October traffic down 15.7% y/y - Reports October: Passengers down 17%; Capacity down 10.2%; Load Factor down 5.2 pts; Departures down 10.7%. All metrics reported on a year-over-year basis. "As observed below and consistent with commentary from our third quarter earnings call, hurricanes Helene and Milton had an outsized impact on our business," stated Drew Wells, Chief Commercial Officer of Allegiant Travel Company. "We canceled nearly 1,000 flights between late September and early January, with approximately two-thirds of those cancelations occurring during the month of October. We are encouraged by booking trends following the election, which suggest a faster-than-expected recovery for the impacted areas. We will continue monitoring these trends with the intent of updating guidance, as needed."

09:01 EST Danone raises offer for Lifeway Foods to $27 per share - In a letter updating on Danone's (DANOY) proposed acquisition of Lifeway Foods (LWAY), which was disclosed in a regulatory filing, Danone stated that it was "disappointed by the Board's response to our Proposal, which offers compelling value to shareholders, especially in light of the positive reaction to our Proposal by the market." Danone's letter added: "We remain convinced that a transaction with Danone will allow Lifeway's shareholders to realize immediate value and to drive Lifeway's continued development. We continue to believe Lifeway has an attractive opportunity to achieve its full potential through a combination with Danone, removing the constraints and additional resources required for a publicly listed company of Lifeway's size. While we have not been granted access to any due diligence yet, in the spirit of demonstrating our strong commitment to the Transaction and continuing to offer a compelling proposition to Lifeway's shareholders, we are prepared to provide the Board with this updated non-binding proposal. Subject to the terms and conditions of our Proposal dated September 23, 2024, which otherwise remain unchanged, we would be prepared to pay $27 per Lifeway share, in all cash, for the entire share capital of the Company. This Updated Indicative Price implies a premium of 72% over the 3-month volume weighted average price as of the last full trading day before we submitted to you our Proposal on September 23, 2024. We believe that this Updated Indicative Price fully reflects the fundamental potential of the Company and provides Lifeway's shareholders with the certainty of an attractive and immediate cash premium. We are committed to ensuring Lifeway's shareholders are offered the opportunity to benefit from our compelling Updated Proposal, and hope you and the rest of the Board will act accordingly. We would welcome the opportunity to discuss this Updated Proposal and next steps with you." Reference Link

08:47 EST Cero Therapeutics receives FDA clearance of IND application for CER-1236 - CERo Therapeutics announces that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug Application for Phase 1 clinical trials of its lead compound, CER-1236, in acute myelogenous leukemia.

08:41 EST Safety Shot expands retail footprint with major grocery chain in US Southwest - Safety Shot announced a new agreement with a leading national grocery chain to sell its convenient, newly branded 4 oz. Sure Shot beverages in select stores across the Southwest. This chain boasts over 2,200 stores nationwide, making them a significant player in the grocery industry. This strategic launch in 192 stores across Nevada, Arizona, and California represents a significant milestone in Safety Shot's growth strategy. It provides access to a substantial and rapidly growing alcohol beverage market and marks a key step towards the Company's goal of nationwide distribution.

08:37 EST Toll Brothers City Living, Daiwa House enter joint venture - Toll Brothers announced a joint venture between its Toll Brothers City Living division and Daiwa House to develop a new luxury condominium community in the New York City metro market. Located on the Hudson River waterfront and offering unobstructed skyline views of Manhattan, Vista Pointe will be a nine-story, 73-unit luxury condominium community at 8 Avenue at Port Imperial in West New York, New Jersey. Toll Brothers is acting as managing member and development lead for the project, overseeing approvals, design, construction, and sales. The partnership has closed on an acquisition and construction loan with Bank OZK arranged through Toll Brothers' in-house Finance Department.

08:34 EST SeaStar Medical reaches milestone of 100th QUELIMMUNE commercial device - SeaStar Medical has begun shipping QUELIMMUNE to a third hospital customer. QUELIMMUNE is the Company's Selective Cytopheretic Device, SCD, for treating critically ill children in the intensive care unit, ICU, with acute kidney injury, AKI, and sepsis. "Within weeks of implementing our direct sales model we have added two commercial customers, underscoring our team's ability to assist hospitals with the Humanitarian Use Device requirements and seamlessly fulfill their orders," said Tim Varacek, SeaStar Medical Senior Vice President, Commercial & Business Operations. "We are delighted that QUELIMMUNE is now available to more children who may benefit from our potentially lifesaving therapeutic device as we continue efforts to secure additional hospital clearances. Our recent progress puts us on track for our goal of having QUELIMMUNE commercially available in the ICUs of four to five leading pediatric hospitals by the end of 2024."

08:32 EST Alpha Modus files patent infringement lawsuit against Brookshire Grocery - Alpha Modus announced it has filed a patent infringement lawsuit against Brookshire Grocery Co. alleging infringement of several Alpha Modus patents pertaining to the Company's '571 patent portfolio, '825 patent portfolio, '672 patent portfolio, '890 patent portfolio and '880 patent portfolio, which encompass retail marketing and advertising data-driven technologies to enhance consumers' in-store experience at the point of decision. The Company's portfolio of patents includes the capability to analyze consumer behavior and product interaction in real-time, allowing businesses to dynamically adjust their marketing strategies to meet the immediate needs of consumers at pivotal purchasing decision moments. The complaint was filed on November 12, 2024, in the United States District Court for the Eastern District of Texas. Alpha Modus is party to a business combination agreement with Insight Acquisition Corp. whereby Alpha Modus plans to become a publicly trading company.

08:13 EST ISS supports NovaBay proposals to sell Avenova business - NovaBay announced that the largest institutional advisory firm, Institutional Shareholder Services, or ISS, has recommended that NovaBay stockholders vote in favor of all of the company's proxy proposals, specifically to authorize and approve the sale of its eyecare business and approve the voluntary liquidation and dissolution of the company. The NovaBay board of directors unanimously supports the asset sale proposal seeking stockholder approval for the sale of substantially all of the company's assets, consisting of the Avenova business, to PRN Physician Recommended Nutriceuticals for a purchase price of $11.5M in cash, subject to adjustment, and the dissolution proposal seeking stockholder approval for the plan of complete liquidation and dissolution of the company in which the company will wind down operations, settle remaining obligations and distribute any remaining proceeds of the liquidation to stockholders, subject to the discretion of the company's board of directors. In making its recommendation to NovaBay stockholders to vote for proposal one and proposal two, ISS stated that the "asset sale appears to be the best available alternative to maximize value for shareholders, the cash form of consideration provides liquidity and certainty of value for NBY shareholders, and there is potential downside risk of non-approval."

08:10 EST 89bio announces new analyses of data from Phase 2b ENLIVEN trial - 89bio announced new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in metabolic dysfunction-associated steatohepatitis, MASH, patients with advanced fibrosis. The findings were presented in four poster sessions at The American Association for the Study of Liver Diseases, AASLD, The Liver Meeting being held in San Diego, California. "We are excited to present additional analyses from our Phase 2b ENLIVEN trial at this year's Liver Meeting, which reinforce pegozafermin's potential effectiveness in reversing fibrosis and preventing progression to cirrhosis in patients with advanced MASH," said Hank Mansbach, Chief Medical Officer of 89bio. "These analyses strengthen our confidence in the design of our Phase 3 trials for both cirrhotic and non-cirrhotic MASH, and we look forward to building on this momentum as we advance these trials."

08:06 EST Calavo Growers appoints Snyder as Chief Financial Officer - Calavo Growers announced that James Snyder will become the Company's new Chief Financial Officer effective December 2. Shawn Munsell, Calavo's current CFO will be departing the Company on November 29 to pursue a new opportunity. He will serve as a consultant to the Company in the month of December to ensure a smooth transition.

08:05 EST Suburban Propane COO Steven Boyd to retire, effective January 1, 2025 - Suburban Propane Partners announced an executive promotion in line with its planned management succession. As previously announced, Steven Boyd, the Partnership's COO, will retire effective January 1, 2025. The Partnership announced that Alejandro Centeno has been promoted to Senior Vice President - Operations as successor to Boyd. In his role, Centeno will report to Michael Stivala, President and CEO. Centeno has been with the Partnership for over 15 years, where he has held several managerial positions within the operations, most recently, rising to the level of Vice President - Operations since August 2023.

08:03 EST Saputo announces normal course issuer bid - Saputo announced that the Toronto Stock Exchange has accepted Saputo's notice of intention to make a normal course issuer bid to purchase up to 2% of Saputo's issued and outstanding common shares. This normal course issuer bid reflects the Company's continued commitment to returning value to shareholders, while maintaining the flexibility to allocate capital for growth opportunities. Under the terms of the NCIB, Saputo may purchase for cancellation up to 8,487,169 common shares, representing 2% of its 424,358,459 issued and outstanding common shares as of November 8, 2024, on the open market through the TSX, alternative Canadian trading systems, or by other means as may be permitted by the applicable securities regulatory authority, including exempt offers and off-exchange block purchases. The NCIB will remain in effect for one year, beginning November 19, 2024, and will end no later than November 18, 2025. In the event the number of common shares that Saputo can purchase under the NCIB has been attained, the Company may apply to the TSX to amend the NCIB to increase the number of common shares authorized to be repurchased in accordance with TSX rules. The consideration that Saputo will pay for any common shares acquired by it on the open market under the NCIB will be in cash at the market price of such common shares at the time of acquisition. In the case of off-exchange block purchases, purchases will be at a discount to the prevailing market price in accordance with and subject to the terms of applicable exemptive relief. Based on the average daily trading volume of 470,487 common shares during the last six months, daily purchases will be limited to 117,621 common shares. In addition, Saputo may make, once per week, a block purchase of common shares not owned, directly or indirectly, by insiders of the Company, in accordance with TSX rules. In connection with the NCIB, Saputo has established an automatic purchase plan. The APP enables Saputo to provide standard instructions regarding how the common shares are to be repurchased on the open market during self-imposed blackout periods. The APP is effective as of November 19, 2024, and should terminate together with the NCIB. It constitutes an automatic plan for purposes of applicable Canadian securities legislation and has been pre-cleared by the TSX. Saputo has not purchased any of its common shares in the last 12 months.

08:02 EST DiamondRock acquires AC Hotel Minneapolis Downtown for $30M - DiamondRock Hospitality announced it has acquired the fee simple interest in the 245-room AC Hotel Minneapolis Downtown for $30M, or approximately $122,000 per key with cash on hand. The Hotel, constructed in 2016, is located in downtown Minneapolis, which has one of the largest concentrations of Fortune 1000 companies in the world and is also a major hub for biotechnology and medical innovation. The acquisition represents a 8.2% capitalization rate on the Hotel's forecasted 2024 net operating income and brings the total number of properties in the company's portfolio to 37 hotels. The acquisition of the Hotel was not contemplated in the Company's updated full-year 2024 guidance issued on November 7. Given the timing of the acquisition, the Hotel will not contribute meaningfully to the company's full year 2024 Adjusted EBITDA or Adjusted FFO per share. However, the Hotel is expected to be included in the company's comparable metrics and add approximately 20 basis points to the company's comparable full-year RevPAR growth and 10 basis points to the comparable full-year Total RevPAR growth.

07:56 EST Jeffs' Brands announces 1-for-13 reverse stock split - Jeffs' Brands intends to effect a one-for-thirteen reverse split of the Company's issued and outstanding ordinary shares, no par value per share, effective as of the close of business on November 19, 2024. The Ordinary Shares will continue to trade on the Nasdaq Capital Market under the existing trading symbol "JFBR" and will begin trading on a split-adjusted basis at the market open on November 20, 2024. The new CUSIP number for the Ordinary Shares following the Reverse Share Split will be M61472136. The trading symbol "JFBRW" and CUSIP number for the Company's public warrants will remain unchanged following the Reverse Share Split. The Reverse Share Split was approved by the Company's shareholders at the Company's Annual Meeting of Shareholders held on July 17, 2024, to be effected at the board of directors' discretion within approved parameters. Accordingly, the board of directors approved a 1-for-13 ratio. The Reverse Share Split will not result in an adjustment to the authorized share capital of the Company under the Company's amended and restated articles of association, as currently in effect, which, as of the date hereof consists of 90,000,000 Ordinary Shares.

07:47 EST Albany announces proposal to discontinue manufacturing operations in Switzerland - Heimbach Switzerland, an affiliate of Albany International, announced that it will initiate consultations with employee representatives regarding a proposal to discontinue manufacturing operations in Olten, Switzerland, and to transfer production to other Heimbach manufacturing facilities. The reduction is subject to local law and will be implemented in accordance with such law and in consultation with the employees' representative body. This action, if approved, will enable the Albany's Heimbach subsidiary to align its paper machine clothing manufacturing capacity with the local market demand and the needs of customers. This initiative to streamline operations is driven by existing and anticipated market conditions, and in no way reflects on the performance of the 83 affected employees, who will be offered separation and outplacement assistance. Until consultations are concluded, the company is unable to reasonably estimate the costs that it would expect to incur in connection with the proposed action. If closure is concluded, the company will disclose the amount, type and timing of any such costs promptly after they are determined.

07:42 EST Nexxen to launch $50M share repurchase program - The Company received approval to launch a new $50 million Ordinary Share repurchase program which is expected to begin on November 19, 2024 and continue until May 19, 2025 or completion. The impending program does not obligate Nexxen to repurchase any particular amount of Ordinary Shares and the program may be suspended, modified or discontinued at any time at the Company's discretion, subject to applicable law. The Company's previous Ordinary Share repurchase program expired on November 1, 2024.

07:39 EST FuelCell announces global restructuring, to reduce workforce by 17% - FuelCell Energy announced a global restructuring of its operations in the U.S., Canada, and Germany that aims to significantly reduce operating costs, realign resources toward advancing the company's core technologies, and protect the company's competitive position amid slower-than-expected investments in clean energy. The restructuring will allow FuelCell Energy to prioritize commercially available technologies to reflect changing market opportunities with an updated strategic plan. The plan involves further expanding the company's Connecticut-manufactured molten carbonate technology to offer distributed power solutions. As a result of these changes, FuelCell Energy expects to reduce operating costs by approximately 15% in fiscal year 2025, compared with fiscal year 2024. These measures include a 17% reduction in FuelCell Energy's workforce, including workforce reduction actions taken in September 2024, as well as reduced spending on product development, overhead and other costs.

07:37 EST Thumzup board of directors approves Bitcoin as treasury reserve asset - Thumzup Media announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin. "As demand for Bitcoin increases and it gains recognition as a leading asset class, we believe it will serve as a robust reserve asset for our treasury," said Robert Steele, Chief Executive Officer of Thumzup Media Corporation. "With the newly sanctioned Bitcoin ETFs and growing backing from institutional investors, Bitcoin presents a strong addition to our treasury approach. Its finite supply and inflation-resistant qualities enhance its role as a reliable asset for preserving value."

07:34 EST Abaxx Technologies provides Q3 corporate update - Abaxx Technologies provides an update on operational milestones and the continued execution of the Company's business strategy in the third quarter following the launch of Abaxx Commodity Exchange and Clearinghouse on June 28, 2024. The Company plans to host an investor call and presentation on Monday, November 18th. Commercial: Onboarded three full clearing members and two additional clearing firms, including our first global bank FCM, with one additional clearing member in progress and expected to be onboarded by year end. Two more bank futures commission merchants are in progress and three additional clearing firms are in discussion for potential onboarding in 2025. Onboarded six merchant trading firms with sixteen more in progress for block trades and central limit order book trading, and onboarded nine financial trading and market making firms with ten more in progress. Completed the onboarding of ten introducing brokers with five more in progress. Exchange Product Development: Listed LNG and carbon contracts enhanced to align with evolving standards. Imminent regulatory submittals planned for lithium and nickel products. Precious metals solutions rollout plan activated. Development efforts in sustainable base metal and weather derivatives initiated. Risk and Regulatory: Efforts underway to expand participation access and connectivity to Abaxx Exchange and Clearinghouse in key jurisdictions beyond Singapore, deepening integration with the global network of clearing houses to promote best practices and standards. Systems and Operations: Initiated second phase system expansion and updates including capabilities for options, multi-currency pricing and settlement, and additional Abaxx ID++ V2 integrations in Abaxx Exchange and Abaxx Clearing software for Abaxx Messenger and ID++ digital signature operations to be used in digital titles. Abaxx console suite applications and ID++ Protocol: Public launch of Abaxx Verifier+ on IOS and Android; Smarter Markets Coffeehouse launch with ID++ membership credential integrations and passwordless login; Production deployment of Abaxx Messenger phase one. Strategic Financing: Progressed Abaxx Singapore strategic financing discussions post onboarding of key merchant commodity traders and a bank clearing firm in late October. As disclosed on October 21st, 2024, announced an Abaxx Technologies strategic placement of 215,000 common shares of the Company at a price of CAD$13.00 per common share for aggregate gross proceeds of C$2,795,000 on a private placement basis, expected to close imminently. Last quarter, following the launch of Abaxx Exchange and Clearinghouse at the end of Q2 2024, Abaxx focused on advancing commercial connectivity across trading firms, clearing firms, and broker networks. Significant progress was made in onboarding and training market participants, furthering our mission to deliver reliable price discovery and risk management tools for today's commodity market participants. In addition, the team advanced the development of additional futures product solutions for battery and precious metals markets, and launched implementations of core software protocols and applications for commercial use in Abaxx Exchange and Abaxx Clearing, SMC, and beyond.

07:10 EST Nouveau Monde provides update on progress toward FID for operations - Nouveau Monde (NMG) reported progress update on its multiple workstreams to bring its Phase-2 Matawinie Mine and Becancour Battery Material Plant to a Final Investment Decision, or FID. The company is actively advancing its integrated feasibility study, engaging with its Anchor Customers Panasonic Energy, a wholly owned subsidiary of Panasonic Holdings, and General Motors Holdings, a wholly owned subsidiary of General Motors (GM), ongoing project financing activities, and preparing for the construction of its Phase-2 operations. Arne Frandsen, Chair of NMG, declared: "Our roadmap is laid out with key components aligning toward the establishment of North America's largest and fully integrated natural graphite production for the electric vehicle ("EV") and lithium-ion battery market. The team is relentless in diligently advancing the technical, commercial and financial deliverables to support a positive FID." Eric Desaulniers, founder, president, and CEO of NMG, stated: "Our focus on engineering, customer engagement, financing, and construction preparation is driving us closer to our goal of becoming a leading supplier of carbon-neutral active anode material. Our time-to-market window remains reasonable and the efforts we invest in refining our facilities and production parameters, CAPEX and OPEX projections, and execution strategy will bear fruit upon reaching FID. Our team, along with our Anchor Customers, strategic investors, lenders, and consultants, are rallied behind our objective of building a competitive, responsible, and quality ore-to-active-anode-materials operation to deliver value to the market and our shareholders."

07:06 EST Opthea appoints Kathy Connell to board of directors - Opthea announced the appointment of Kathy Connell to the Board of Directors as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the Company on November 15, 2024. Connell is currently Senior Client Partner and Head of Healthcare and Life Sciences Australia/New Zealand at Korn Ferry. The Company also notes that Megan Baldwin, PhD, retired from the Board as Executive Director, in accordance with ASX Listing Rules. Dr. Baldwin will continue to advance Opthea's innovation agenda in her executive role as Founder and CIO of the Company.

07:04 EST Eyenovia plans to terminate Phase 3 CHAPERONE study after DRC review - Eyenovia announced that a review of the CHAPERONE data by an independent Data Review Committee found that the trial is not meeting its primary endpoint of a less than 0.5 diopter progression in visual acuity over three years. CHAPERONE is Eyenovia's Phase 3 study evaluating its proprietary drug-device combination of low-dose atropine in the Company's Optejet dispensing platform as a potential treatment for pediatric progressive myopia. The DRC reviewed the safety and efficacy data from 252 evaluable patients. The DRC found that the rate of myopia progression was not significantly different between the two active treatment arms and placebo. In the safety analysis, all dosages and placebo appeared to be well-tolerated, with a mild and infrequent adverse event profile. Full study data has not yet been released to Eyenovia. "We are disappointed that the DRC determined that the CHAPERONE study does not appear to be meeting its primary efficacy endpoint," stated Michael Rowe, CEO. "We plan to terminate the study, review the data more thoroughly, and evaluate next steps. On behalf of the entire company, I would like to express my sincere appreciation to the children, parents, caregivers and healthcare professionals who participated in this trial, as well as all the Eyenovia team members for their exceptional work on this program." In light of the results of this review, the Company is considering a variety of steps to maximize value to all stakeholders, to reduce expenses and to evaluate its strategic options, which may include a business combination, reverse merger, asset sales or a combination of those alternatives. Further information will be made available once the evaluation of strategic options has been completed.

06:47 EST Equity Commonwealth authorizes initial cash liquidating distribution of $19.00 - Equity Commonwealth announced that its Board of Trustees has authorized an initial cash liquidating distribution of $19.00 per common share which will be paid on December 6 to shareholders of record on November 25. The company is also updating the estimated aggregate shareholder liquidating distribution range of $19.50 to $21.00 per common share disclosed in its definitive proxy statement filed on October 2 to an estimated aggregate shareholder liquidating distribution range of $20.00 to $21.00 per common share. In addition, the company announced today that, in connection with the Initial Liquidating Distribution, the New York Stock Exchange has determined that the ex-dividend date for the Initial Liquidating Distribution will be December 9, the first business day after the payment date.

06:38 EST Hyperscale Data announces special dividend of Class B common stock - Hyperscale Data announces that it plans to issue a special one-time dividend of 5M shares of its Class B Common Stock to all holders of its Class A Common Stock and the Series C Convertible Preferred Stock on an as-converted basis. The record date for the Distribution is November 29. Stockholders who own the company's Class A Common Stock at the close of trading on that date will be eligible to receive the shares of Class B Common Stock. Further, the company has set a payment date of December 16, subject to adjustment.

06:00 EST Meta's Threads has had over 15M signups in November, says Mosseri - In a post on Thursday, Instagram and Threads boss Adam Mosseri said that Threads had "more than 15M signups in November alone" and it is "going on three months with more than a million signups a day." Mosseri added: "Know we have a lot more work to do, and our teams are working hard to get this community what they need. Appreciate you all." Reference Link

05:36 EST Ingredion, Lantmannen enter strategic partnership to develop plant-based protein - Ingredion and Lantmannen announce a new long-term collaboration. Lantmannen is an agricultural cooperative and Northern Europe's player in agriculture, bioenergy, food and ingredients. The collaboration will begin with the fulfillment of European market needs for pea protein isolates and various facets of sales, product innovation, and process enhancement. Lantmannen will invest more than 100M euros in a factory in Sweden, while partnering with Ingredion to develop a differentiated portfolio of plant-based protein isolates based on yellow peas. Construction of the production plant will be completed in 2027.

05:23 EST Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review - Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria, or CSU, whose disease is not adequately controlled with H1 antihistamine treatment. The target action date for the FDA decision is April 18, 2025. The resubmitted sBLA is supported by data from the multi-trial, LIBERTY-CUPID Phase 3 clinical program for Dupixent in CSU. The sBLA adds results from Study C, which was conducted in patients with uncontrolled CSU who were on standard-of-care antihistamines. Study C, the second LIBERTY-CUPID pivotal trial in biologic-naive patients, met its primary and key secondary endpoints confirming results seen in the previous Study A. Results showed Dupixent significantly reduced itch and urticaria activity. Safety results in all LIBERTY-CUPID Phase 3 trials were generally consistent with the known safety profile of Dupixent in its approved indications. Adverse events more commonly observed with Dupixent compared to placebo were injection site reactions and COVID-19 infection.

05:15 EST Rio Tinto, GravitHy team to speed the decarbonization of steelmaking in Europe - Rio Tinto has entered into definitive agreements with GravitHy, an early-stage industrial company, to help accelerate GravitHy's steel decarbonisation project in France. As part of this collaboration, Rio Tinto will supply high-grade direct reduction iron ore pellets from its Iron Ore Company of Canada, or IOC, operations to GravitHy's planned operation, as well as manage the sales and marketing of ultra-low carbon Hot Briquetted Iron, or HBI, GravitHy produces. GravitHy's proposed two million tons per year iron production facility at Fos-sur-Mer, France, is planned to be commissioned in 2028. The facility, which is located next to a deep seaport, will feature ultra-low carbon hydrogen production infrastructure, powered by existing grid-connected nuclear power, to process direct reduction pellets into HBI. This process has the potential to reduce ironmaking-related CO2 emissions by more than 90%. Steel produced with low-carbon emissions is an essential component of the net-zero energy transition. The production of iron and steel contributes around 8% of global carbon emissions and requires new technologies, redesigned processes, and new infrastructure to decarbonize.

05:06 EST NCR Atleos announces new five-year agreement with Atleos Cashzone Network ATMs - NCR Atleos announced a new five-year agreement to provide Atleos' Cashzone Network ATMs in the John Lewis Partnership's Waitrose supermarkets across the UK. The John Lewis Partnership owns and operates two of Britain's retail brands - John Lewis and Waitrose. The company and Atleos have built a relationship, with Atleos installing ATMs in Waitrose locations.